Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
Study sponsor: Karyopharm Therapeutics Inc · KPTI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-07-31Actual
Enrollment · participants80Actual
Source updated2026-10-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.